

Monthly DRUP newsletter 68, 01 November 2021

Study update

To date a total of 1858 cases have been submitted to the study team and more than 900 of these have started a treatment within the DRUP study. For the 3rd stage Nivolumab cohort we are about to reach an inclusion of 130 patients and the cohort is therefore currently on hold. New submissions will be placed on a waiting list until further notice.

Recently the Crizotinib cohort for METmut NSCLC mutations was also put on hold, however a few slots have become available, so if you have a potential case: do not hesitate to submit it to the study team.

Next to the above we are also pleased to share with you that we are only a few preparatory steps away from starting inclusion for the new DRUP compound erdafitinib. Patients who have FGFR1-4 amplified tumors will be eligible for treatment with this drug.

Protocol amendment

This month we will submit the 15th protocol amendment! This amendment includes, amongst other things, the addition of 2 new study drugs; selpercatinib and niraparib. We hope to be able to add these new treatment options to the study in the very near future. We will keep you posted on the progress!

Information for participating sites

We would like to use this opportunity to remind all participating sites that patients in the 3rd stage nivolumab cohort are only receiving study medication (ordered via alea) for the first 16 weeks of treatment, and thereafter they will continue on regular medication (ordered via the local pharmacy). Next to this we would also like to again remind all participating sites to submit drug (re-) orders in time, as there is a minimum of 5 working days delivery time. Express delivery of medication will from now onwards only be possible by exception and not on a regular base.

Furthermore, it has come to our attention that some sites might have a lot of leftover DRUP study medication in stock, and therefore we would like to ask you to pay extra attention to this in the future and to check the local stock before ordering new medication. In case of sufficient local stock, a notification can be made about this on the drug order form.

Finally, we have received many questions about COVID-19 vaccination while being treated within DRUP, and in this context we would like to inform you that the study team has no objection to this. Furthermore, the advice from the DRUP team on this subject is in alignment with the advices and recommendations issued by the Dutch Society of Medical Oncology (NVMO). Detailed information for specific patient situations is available through the following link: [COVID-19-vaccinatie van immuungecompromitteerde patiënten | LCI richtlijnen \(rivm.nl\)](#).


Best regards,

Henk Verheul, Hans Gelderblom and Emile Voest, principle Investigators
Maxime van Berge Henegouwen, Laurien Zeverijn, Gijs de Wit and Birgit Geurts, study coordinators
Lena Bilet, trial manager


List of pharmaceutical companies & study drugs			
Confidential, list might be subjected to change			
Currently available			
<u>Amgen</u>	<u>Eisai</u>	<u>Bayer</u>	<u>Roche</u>
Panitumumab	Lenvatinib	Regorafenib	Erlotinib
			Trastuzumab +
<u>BMS</u>	<u>AstraZeneca</u>	<u>Clovis Oncology</u>	Pertuzumab
Nivolumab	Olaparib	Rucaparib	Vemurafenib +
Ipilimumab	Durvalumab		Cobimetinib
		<u>MSD</u>	Vismodegib
<u>Novartis</u>	<u>Pfizer</u>	Pembrolizumab	Atezolizumab +
Dabrafenib	Axitinib		bevacizumab
Nilotinib	Crizotinib	<u>Lilly</u>	Alectinib
Trametinib	Sunitinib	Abemaciclib	Entrectinib
Ribociclib	Palbociclib		
Alpelisib	Talazoparib,	<u>BI</u>	<u>Janssen</u>
	dacomitinib	Afatinib	Erdaftinib
	Lorlatinib		
Committed			
<u>Lilly</u>	<u>GSK</u>		
Selpercatinib	Niraparib		

Calendar & publicity
NOVEMBER
Submission protocol amendment 15: adding of new study compounds

Submission and accrual overview
November 1st, 2021



Submissions and accrual 3rd stage cohort Nivolumab for MSI tumors
November 1st, 2021



Participating sites

Currently open for inclusion (n = 35)			
• AMC	• Haaglanden MC	• Reinier de Graaf	• ZG Twente
• AVL	• Haga ziekenhuis	• Rijnstate	• Zuyderland
• Amphia	• Isala	• Spaarne Gasthuis	• Rivas Zorggroep
• Bravis	• Martini	• St. Antonius	• OLVG
• Deventer Ziekenhuis	• Maxima MC	• UMC Groningen	• VUMC
• Erasmus MC	• MC Leeuwarden	• UMC Leiden	In preparation (n=2)
• ETZ	• Meander	• Maastricht UMC	• Maasstad
• Franciscus	• Nij Smellinghe	• Radboud UMC	• Bernhoven
• Gelderse Vallei	• Treant Zorggroep	• UMC Utrecht	
• Gelre Ziekenhuizen	• NWZ	• VieCuri	

DRUGS OPEN FOR INCLUSION			
Nilotinib	KIT _{mut} GIST	PDGFRA _{mut} GIST	PDGFRA _{mut} mesothelioma
	PDGFRB _{amp} CRC	KIT _{mut} melanoma	KIT _{mut} kiemcel tumor
Nivolumab	MSI tumors	HML tumors	3 rd stage MSI tumors
Nivolumab + ipilimumab	HML tumors		
Olaparib	ATM _{mut} tumors	BRCA _{mut} tumors	HRR deficient tumors (2x)
Panitumumab	RAF/RAS _{wt} sarcoma	RAF/RAS _{wt} HNSCC	EGFR _{mut} NSCLC
	RAF/RAS _{wt} thyroid ca	RAF/RAS _{wt} salivary duct ca	RAF/RAS _{wt} cervical ca
	RAF/RAS _{wt} endometrial ca	RAF/RAS _{wt} meningioma	RAF/RAS _{wt} eye melanoma
	RAF/RAS _{wt} GBM	RAF/RAS _{wt} vulvar ca	RAF/RAS _{wt} ACUP
	RAF/RAS _{wt} anal ca		
Pembrolizumab	HML CRC	HML eso/card/stomach	HML HNSCC
	HML prostate ca	HML breast ca	HML miscellaneous
	HML > 290 (all type)		
Regorafenib	RET+ NSCLC	RET+ neuroblastoma	KIT _{mut} melanoma
	KIT _{mut} Thymuscarcinoma	BRAF _{mut} ACC	FLT1 _{amp} duodenal carcinoma
Dabraf + Tramet	BRAF _{mut} NSCLC	BRAF _{mut} GBM	BRAF _{mut} low grade glioma
	BRAF _{mut} NEC	BRAF _{mut} cholangiocarcinoom	BRAFV600E _{mut} breast cancer
	BRAFV600E _{mut} grade 3 glioma		
Dabrafenib	BRAF _{mut} GBM	BRAF _{mut} UCC	
Trametinib	NRAS _{mut} ovarian ca	MAP2K1 _{mut} NSCLC	NRAS _{mut} NSCLC
	MAP3K1 _{mut} NEC	MAP3K1 _{mut} cervical ca	MAP2K1 _{mut} CRC
	MAP2K4 _{mut} CRC	MAP3K1 _{mut} ACUP	MAP2K4 _{mut} cholangioca
	MAP2K4 _{mut} ovarian ca	MAP3K1 _{mut} breast ca	MAP2K4 _{mut} breast ca
	NRAS _{mut} thyroid cancer	MAP3K1 _{mut} prostate	NRAS _{mut} pleomorphic tumor
	NRAS _{mut} prostate	BRAF _{fusie} (pilocytair) astrocytoom	NRAS _{mut} yolk sac tumor
	GNA11 _{mut} melanocytair tumor	NRAS _{mut} cholangio cancer	BRAF _{exon 12} deletion NSCLC
	BRAF _{fusie} NSCLC	NRAS _{mut} salivary duct ca	MAP2K4 _{loss} pancreas cancer
	NF1 _{mut} low grade glioma	BRAF _{fusie} pancreas cancer	MAP2K1 _{mut} pancreas cancer
	MAP2K1 _{mut} stomach cancer		
Trastuz. + Pertuz.	HER2 _{amp} CRC	HER2 _{amp} cholangio ca	HER2 _{mut} NSCLC
	HER2 _{mut} ovarian ca	HER2 _{amp} salivary duct ca	HER2 _{amp} NSCLC
	HER2 _{mut} CRC	HER2 _{mut} cervical ca	HER2 _{amp} vulvar ca
	HER2 _{amp} cervical ca	HER2 _{amp} hidradenoca	HER2 _{amp} UCC
	HER2 _{amp} ovarian ca	HER2 _{amp} NEC	HER2 _{mut} UCC
	HER2 _{mut} ACC	HER2 _{amp} duodenal cancer	
Vemur. + Cobimet.	BRAF _{mut} salivary duct	BRAF _{mut} ACUP	BRAF _{mut} ovarian ca
	BRAF _{mut} thyroid ca	BRAF _{non-V600mut} NSCLC	BRAF _{V600Emut} Erdheim Chester Disease
Vismodegib	PTCH1 _{mut} Sarcoma	PTCH1 _{mut} medulloblastoma	
Erlotinib	EGFR _{mut} GBM	CRC with EGFR mutations	EGFR fusions GBM
Lenvatinib	FGFR1 _{amp} CRC	FGFR2 _{amp} CRC	FGFR2 _{amp} breast ca
	FGFR1 _{amp} Osteosarcoma	FGFR1 _{amp} NSCLC	FGFR3 _{mut} anal ca
	FGFR2 _{amp} esophageal ca	FGFR2 _{mut} endometrial ca	FGFR3 _{amp} SGT
	FGFR2 _{fusie} ACUP	FGFR2 _{fusie} cholangioca	FGFR1 _{amp} breast ca
	FGFR2 _{amp} Urachal ca	FGFR3 _{mut} UCC	FGFR2 _{mut} ACC
	FGFR3 _{amp} NEC nasal cavity	FGFR1 _{mut} glioneural tumor	FGFR3 _{mut} HNSCC
	FGFR3 _{fusie} GBM	FGFR2 _{mut} digital papillary cancer	FGFR2 _{fusion} pancreas cancer
	FGFR2 _{amp} NSCLC	FGFR3 _{fusie} cholangioca	FGFR2 _{mut} cholangioca/biliary tract
	FGFR1 _{amp} pancreas cancer	FGFR2 _{mut} salivary duct cancer	
Sunitinib	KIT _{mut} thymus ca	PDGFRA _{mut} prostate ca	FGFR1 _{amp} UCC
	PDGFRB _{amp} breast ca	PDGFRB _{mut} osteosarcoma	PDGFRA _{amp} ACC
	FGFR1 _{amp} Ovarian cancer	PDGFRA _{amp} thyroid cancer	FTL3 _{amp} CRC
	CSF1R _{mut} CRC	KIT _{amp} NSCLC	FGFR2 _{amp} ovarian cancer
Crizotinib	ALK _{fus} IMT	MET _{amp} CRC	ALK _{mut} CRC
	MET _{mut} NSCLC	MET _{amp} esophageal ca	MET _{amp} NSCLC
	ALK _{mut} thyroid	ALK _{fus} leiomyosarcoma	ALK _{fusion} CUP
	MET _{fusion} anaplastic thyroid cancer	MET _{amp} HCC	MET _{amp} GEJ-tumor
	MET _{amp} Ovarium cancer	MET _{mut} (papillair) kidney cell cancer	
Axitinib	FLT1 _{amp} CRC		
Rucaparib	HRR _{alt} ovarian cancer	HRR _{alt} prostate cancer	HRR _{alt} pancreatic cancer
	HRR _{alt} miscellaneous	HRR _{alt} Breast cancer	
Alectinib	ALK fusion (all tumor types)		
Abemaciclib	CCND1 _{amp} UCC	CCND1 _{amp} NSCLC	CCND1 _{amp} prostate cancer
	CCND1 _{amp} melanoma	CCND3 _{amp} small intestine	CDK4 _{amp} (lipo)sarcomen
Alpelisib	Miscellaneous tumors with PIK3CA _{mut}	PIK3CA _{mut} SCC gynecologic tumors	PIK3CA _{mut} gynecologic tumors
	PIK3CA _{mut} upper-GI tumors	PIK3CA _{mut} HNSCC	PTEN _{loss} prostate cancer
Talazoparib	Tumors with HRD signature		
Legend	Cohort closed	Cohort on hold	Slots available

DRUGS CLOSED FOR INCLUSION			
Palbociclib	CDKN2A _{loss} GBM	CDKN2A _{loss} CRC	CDKN2A _{loss} PEComa
	SMARCA4 _{mut} ovarian ca	CDKN2A _{mut} cholangio ca	CDKN2A _{mut} melanoma
	CDKN2A _{loss} duodenal ca	CCND1 _{ampl} NSCLC	CDKN2A _{loss} RCC
	CDKN2A _{loss} HNSCC	CDKN2A _{del} esophageal ca	CCND1 _{ampl} melanoma
	CDKN2A _{mut} uveal melanoma	CDK4 _{ampl} Sarcoma	CCND1 _{ampl} NET
	CDKN2A _{loss} pancreatic ca	CDKN2A _{loss} vulvar ca	CDK4 _{ampl} astrocytoma
	CDKN2A _{del} NSCLC	CDK4 _{ampl} prostate cancer	CDK4 _{ampl} esophageal cancer
	CDKN2A _{loss} pNET	CDKN2A _{loss} ovarian cancer	CCND2 _{ampl} CRC
CDK6 _{ampl} prostate cancer	SMARCA4 _{mut} CRC		
Durvalumab	MSI tumors		
Cabozantinib	MET _{ampl} melanoma	RET _{fusion} NSCLC	MET _{ampl} teratoma
	NTRK2 _{mut} GIST	MET _{mut} oesofagus cancer	
Ribociclib	CDKN2A _{loss} prostate cancer	CDKN2A _{loss} ependymoma	CDK4 _{ampl} melanoma
	CDKN2A _{del} anaplastic meningioma	CDKN2A _{loss} thymus carcinoma	CDKN2A _{loss} Ewing Sarcoma
	CDKN21 _{del/mut} bladder cancer	CDK6 _{amp} mucoepidermoid cancer	CDKN2A _{del} mesothelioma
	CDKN2A _{loss} ceruminous cancer	CDKN2A _{del} salivary gland cancer	
Afatinib	NRG1 _{fusie} NSCLC	NRG1 _{fusie} breast ca	NRG1 _{fusie} GI tumors
	NRG1 _{fusie} miscellaneous (all tumors)	HER4 _{mut} NSCLC	
Legend	Cohort closed	Cohort on hold	Slots available